News
There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...
Thanks to the tireless efforts of people like San Luis Obispo resident Frank Kalman and his nonprofit, End Kids Cancer, there have been major advances in pediatric oncology in recent years. Here's Kal ...
Crown BioScience experts explore organoid models and high-content imaging to evaluate T-cell-targeted therapies and ...
Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...
WITH an impressive attendance of 20,522 participants from 131 countries, the European Congress of Radiology (ECR) 2025 was an ...
Researchers have discovered that 'DEAD-box helicases 54 (DDX54)', a type of RNA-binding protein, is the master regulator that hinders the effectiveness of immunotherapy -- opening a new path for lung ...
Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...
The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...
CTLA4 Inhibitors Market forecast to 2035 covers market size, key trends, competitive landscape, and growth opportunities in cancer immunotherapy and autoimmune diseases.
Immune checkpoint inhibitors ... of lung cancer cells. They demonstrated that suppressing DDX54 enhances immune cell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results